Amgen Commits To PCSK9 Phase III, Tightening First-To-Market Race
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The biotech will begin Phase III studies testing the cholesterol treatment in early 2013, about six months after Sanofi/Regeneron initiated Phase III studies of a rival drug.